The positive results are a major leap forward for Takeda's orexin programme, which looked in jeopardy in 2021 when lead asset ...

The Oligonucleotides for CNS Summit returns for its 5 th year to address key challenges in durability, scalability, potency ...

The readout is particularly welcome for AZ as baxdrostat (formerly CIN-107) showed mixed results in earlier hypertension ...

The US regulator has cleared use of Kerendia (finerenone) for the treatment of heart failure patients who have a left ...

It is not certain that the new Wearable Behaviour Model (WBM) AI will make it into a finished product – not least because of ...

It is the second licensing deal that AbbVie has negotiated this year for a trispecific for multiple myeloma, coming in the ...

The acquisition – which will see MSD pay $107 for each American Depository Share (ADS) in UK-headquartered Verona – is the ...

Biogen has been trying to build up its R&D pipeline as it faces increased competition for its biggest-selling products like Spinraza (nusinersen) for spinal muscular atrophy (SMA) and its multiple ...

Returning for its second year, the Autoimmunity & Inflammation Partnering & Investment Summit unites over 80 on-scope and ...

So, what were the major themes to come out of BIO Boston 2025? Who’s getting excited about what? And – besides the obvious ...

The FDA has called a plan to publish certain complete response letters (CRLs) for medicines it has rejected after an initial ...

Toymaker Mattel has launched its latest addition to the Barbie range of dolls, the first with type 1 diabetes, which comes ...